Diltiazem hydrochloride tablet adverse reactions: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 11: Line 11:
The following represent occurrences observed in clinical studies of [[angina ]]patients. In many cases, the relationship to CARDIZEM has not been established. The most common occurrences from these studies, as well their frequency of presentation, are [[edema ]](2.4%), [[headache ]](2.1%), [[nausea ]](1.9%), [[dizziness ]](1.5%), [[rash ]](1.3%), and [[asthenia ]](1.2%). In addition, the following events were reported infrequently (less than 1 %):
The following represent occurrences observed in clinical studies of [[angina ]]patients. In many cases, the relationship to CARDIZEM has not been established. The most common occurrences from these studies, as well their frequency of presentation, are [[edema ]](2.4%), [[headache ]](2.1%), [[nausea ]](1.9%), [[dizziness ]](1.5%), [[rash ]](1.3%), and [[asthenia ]](1.2%). In addition, the following events were reported infrequently (less than 1 %):


'''Cardiovascular:''' [[Angina]], [[arrhythmia]],[[ AV block ]]([[first-degree AV block| first-degree]]), AV block ([[second degree AV block|second-]] or [[third degree AV block|third-degree –]] see [[Diltiazem hydrochloride tablet warnings|WARNINGS]], Cardiac Conduction), [[bradycardia]], [[bundle branch block]], [[congestive heart failure]], [[ECG]] abnormality, [[flushing]], [[hypotension]], [[palpitations]], [[syncope]], [[tachycardia]], [[ventricular extrasystoles]].
'''Cardiovascular:''' [[Angina]], [[arrhythmia]],[[ AV block ]]([[first-degree AV block| first-degree]]), AV block ([[second degree AV block|second-]] or [[third degree AV block|third-degree –]] see [[Diltiazem hydrochloride tablet warnings|WARNINGS, Cardiac Conduction]]), [[bradycardia]], [[bundle branch block]], [[congestive heart failure]], [[ECG]] abnormality, [[flushing]], [[hypotension]], [[palpitations]], [[syncope]], [[tachycardia]], [[ventricular extrasystoles]].


'''Nervous System:''' Abnormal dreams, [[amnesia]], [[depression]], [[gait ]]abnormality, [[hallucinations]], [[insomnia]], [[nervousness]], [[paresthesia]], personality change, [[somnolence]], [[tremor]].
'''Nervous System:''' Abnormal dreams, [[amnesia]], [[depression]], [[gait ]]abnormality, [[hallucinations]], [[insomnia]], [[nervousness]], [[paresthesia]], personality change, [[somnolence]], [[tremor]].


'''Gastrointestinal:''' [[Anorexia]], [[constipation]], [[diarrhea]], [[dysgeusia]], [[dyspepsia]], mild elevations of [[alkaline phosphatase]], [[SGOT]], [[SGPT]], and [[LDH ]](see [[Diltiazem hydrochloride tablet warnings|WARNINGS]], Acute Hepatic Injury), [[thirst]], [[vomiting]], weight increase.
'''Gastrointestinal:''' [[Anorexia]], [[constipation]], [[diarrhea]], [[dysgeusia]], [[dyspepsia]], mild elevations of [[alkaline phosphatase]], [[SGOT]], [[SGPT]], and [[LDH ]](see [[Diltiazem hydrochloride tablet warnings|WARNINGS, Acute Hepatic Injury]]), [[thirst]], [[vomiting]], weight increase.


'''Dermatological:''' [[Petechiae]], [[photosensitivity]], [[pruritus]], [[urticaria]].
'''Dermatological:''' [[Petechiae]], [[photosensitivity]], [[pruritus]], [[urticaria]].

Revision as of 16:21, 5 March 2014

Diltiazem
CARDIZEM tablet® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings
Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
CARDIZEM LA tablet extended release® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings
Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
How Supplied/Storage and Handling
Labels and Packages
DILTIAZEM HYDROCHLORIDE injection® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings
Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Diltiazem
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]

ADVERSE REACTIONS

Serious adverse reactions have been rare in studies carried out to date, but it should be recognized that patients with impaired ventricular function and cardiac conduction abnormalities usually have been excluded.

In domestic placebo-controlled angina trials, the incidence of adverse reactions reported during CARDIZEM therapy was not greater than that reported during placebo therapy.

The following represent occurrences observed in clinical studies of angina patients. In many cases, the relationship to CARDIZEM has not been established. The most common occurrences from these studies, as well their frequency of presentation, are edema (2.4%), headache (2.1%), nausea (1.9%), dizziness (1.5%), rash (1.3%), and asthenia (1.2%). In addition, the following events were reported infrequently (less than 1 %):

Cardiovascular: Angina, arrhythmia,AV block ( first-degree), AV block (second- or third-degree – see WARNINGS, Cardiac Conduction), bradycardia, bundle branch block, congestive heart failure, ECG abnormality, flushing, hypotension, palpitations, syncope, tachycardia, ventricular extrasystoles.

Nervous System: Abnormal dreams, amnesia, depression, gait abnormality, hallucinations, insomnia, nervousness, paresthesia, personality change, somnolence, tremor.

Gastrointestinal: Anorexia, constipation, diarrhea, dysgeusia, dyspepsia, mild elevations of alkaline phosphatase, SGOT, SGPT, and LDH (see WARNINGS, Acute Hepatic Injury), thirst, vomiting, weight increase.

Dermatological: Petechiae, photosensitivity, pruritus, urticaria.

Other: Amblyopia, CPK elevation, dry mouth, dyspnea, epistaxis, eye irritation, hyperglycemia, hyperuricemia, impotence, muscle cramps, nasal congestion, nocturia, osteoarticular pain, polyuria, sexual difficulties, tinnitus.

The following postmarketing events have been reported infrequently in patients receiving CARDIZEM: acute generalized exanthematous pustulosis, allergic reactions, alopecia, angioedema (including facial or periorbital edema), asystole, erythema multiforme (including Stevens-Johnson syndrome, toxic epidermal necrolysis), extrapyramidal symptoms, gingival hyperplasia, hemolytic anemia, increased bleeding time, leukopenia, photosensitivity (including lichenoid keratosis and hyperpigmentation at sun-exposed skin areas), purpura, retinopathy, myopathy, and thrombocytopenia. There have been observed cases of a generalized rash, some characterized as leukocytoclastic vasculitis. In addition, events such asmyocardial infarction have been observed, which are not readily distinguishable from the natural history of the disease in these patients. A definitive cause and effect relationship between these events and CARDIZEM therapy cannot yet be established. Exfoliative dermatitis (proven by rechallenge) has also been reported.[1]

References

  1. "CARDIZEM (DILTIAZEM HYDROCHLORIDE) TABLET, COATED [BTA PHARMACEUTICALS]". Retrieved 5 March 2014.